Product Information
TOBRAMYCIN 80 MG/2 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $0.8315 per ML under NDC 63323030602. Its NADAC has been published 315 times since Nov 28, 2013.
FDA first approved this application on Nov 29, 2002. Its Orange Book therapeutic-equivalence code is AP.
Strength
40 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323030602
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
TOBRAMYCIN SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA065122FDA Approved
11/29/2002
TE Code
AP
On Market Since
11/23/2005
Pharmacological Classes
Price Statistics
The NADAC for TOBRAMYCIN 80 MG/2 ML VIAL has been published 315 times since Nov 28, 2013, and over the history we have for it it has declined 34.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8315 per ML |
|---|---|
| All-time high | $1.4932 (Jan 15, 2014) |
| All-time low | $0.5997 (Mar 18, 2026) |
| 52-week high | $0.8372 |
| 52-week low | $0.5997 |
| Median price | $0.8442 |
| Average price | $0.8449 |
| Largest weekly change | +101.1% (Aug 20, 2014) |
| Weeks tracked | 315 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the TOBRAMYCIN SULFATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
TOBRAMYCIN SULFATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoglycoside Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOBRAMYCIN 80 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for TOBRAMYCIN 80 MG/2 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $0.8315 per ML (NDC 63323030602), effective Sep 30, 2026.
How has the price of TOBRAMYCIN 80 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for TOBRAMYCIN 80 MG/2 ML VIAL has declined 34.8%. It has been tracked across 315 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TOBRAMYCIN 80 MG/2 ML VIAL?
Since Nov 28, 2013, the NADAC for TOBRAMYCIN 80 MG/2 ML VIAL has ranged from a low of $0.5997 (Mar 18, 2026) to a high of $1.4932 (Jan 15, 2014), with a median of $0.8442 per ML.
Are there cheaper alternatives to TOBRAMYCIN 80 MG/2 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of TOBRAMYCIN 80 MG/2 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TOBRAMYCIN 80 MG/2 ML VIAL?
TOBRAMYCIN 80 MG/2 ML VIAL (NDC 63323030602) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.